Campus alert status is yellow: For the latest campus alert status, news and resources, visit

Search Close Search
Search Close Search
Page Menu

Li Zhong





UMassMed Faculty Page


Title: Critical Amino Acid Residues Contribute to Crossing Vascular Barrier by AAV9 Vector. UMMS12-73; Patent Pending.

  • New rAAV vector technology desirable for gene therapy applications addressing muscular and lung disorders. A novel AAV9 capsid mutant produces local tissue-restricted expression and genome persistence, delivered by intravascular (IV), intramuscular (IM) and intranasal (IN) route. The therapy is effective while producing low levels of expression in liver. 


Innovation TopicsGene TherapyAAVGene therapy improvementGene editing